The COVID Bottleneck Worth Billions for These Biotech Stocks

Energy and Capital editor Keith Kohl pulls back the curtain to reveal a devastating crisis inside the biotech industry. Energy and Capital editor Keith Kohl pulls back the curtain to reveal a devastating crisis inside the biotech industry. [Energy and Capital logo] The COVID Bottleneck Worth Billions for These Biotech Stocks [Keith Kohl Photo] By [Keith Kohl]( Written Oct 20, 2021 Most investors only dream about a day like May 6, 2020. For a small group of biotech investors, it was the single most profitable day of their lives. You see, a few months prior to that date, a small company by the name of MacroGenics had submitted its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA). This wasn’t some off-the-shelf generic aspirin, mind you. The company was developing a drug called margetuximab to improve outcomes for late-stage breast cancer patients with a genetic mutation called HER2. On May 5, you would’ve been able to pick up shares of MacroGenics for under $7.50 a pop. By 1 p.m. the next day, shares had soared nearly 180%! [mgnxstock] It turns out the company was on track to report some very good news regarding the Phase 3 SOPHIA study of margetuximab in HER2-positive breast cancer by the end of the year. If approved, the company would then be able to commercially launch its drug and rake in millions in revenue. Elon Musk Drops MASSIVE Bombshell The shrewd billionaire just made a VERY strange confession about the future of his electric car empire. The secret he reveals could also mint fortunes for smart, fast-moving investors. This has nothing to do with buying shares of Tesla. [Click here]( for the stunning details. On December 16, 2020, MacroGenics announced it had been given the green light to launch margetuximab. That approval was the linchpin for a windfall of cash to reach the company's pockets. Unfortunately, these success stories have been few and far between during the pandemic. And it’s all because of one massive bottleneck that has stalled the development of critical new drugs, costing the industry billions of dollars. But you know how that saying goes, don’t you? Every crisis breeds opportunity. However, this opportunity won’t remain open much longer. A Biotech Crisis Costing Billions What were your first thoughts when the COVID lockdowns were hammered into place in March 2020? While most people were concerned about how many pallets of toilet paper they could amass at the nearby Costco, a crisis was brewing in the biotech industry. You see, in order to approve a new drug, the FDA must conduct an on-site inspection of the manufacturing facilities. When the FDA announced that it had suspended all its inspections due to COVID-19, it had a catastrophic effect that rippled throughout the biotech sector. A Brand-New Internet Is Coming This December [This is it](... the beginning of the future. On December 5, 2021, a brand-new, revolutionary form of the internet will finally make its debut. Nothing will be the same when it’s all over. No street, no building, no car, no human will go unaffected. It could be the greatest technological leap forward since the advent of television, and it’s all in the hands of a single [Arizona-based tech company.]( Rather than getting the stamp of approval, companies suddenly started learning that their approval decisions were being deferred. And if your company was planning on manufacturing your product outside the U.S., having your facility's inspection postponed felt like a killing blow to your launch timeline. According to a report from the Government Accountability Office, the FDA was unable to complete more than 1,000 of its planned inspections in 2020. This was a huge deal too. By May 2020, approximately 74% of facilities manufacturing active pharmaceutical ingredients and 54% of those manufacturing finished drugs for the U.S. market were located outside of the United States. You can probably guess what happened next. The bottleneck that developed swelled to epic proportions. This was a wake-up call for the FDA, and you don’t need me to tell you the kind of opportunity staring back at investors in the biotech industry. But if you’re trying to ponder just how lucrative this market will become in the near future, let’s put some concrete numbers on it, shall we? According to growth estimates, the biotech market is projected to reach $2.4 trillion by 2028! Like any sector ripe with profits, these inspections are “make it or break it” events that could end one of two ways… Wild, unimaginable growth or utter bankruptcy. The good news is that there’s a shining light at the end of this tunnel, and the FDA is only now starting to address this crisis. Tomorrow morning, I’m going to lay out all the details to this situation and show you exactly which companies will be the first to break through the FDA’s bottleneck. Stay tuned. Until next time, [Keith Kohl Signature] Keith Kohl [[follow basic]@KeithKohl1 on Twitter]( --------------------------------------------------------------- How You Can Win 4 Out of 5 Trades Have you become frustrated with the increasing volatility of the markets lately? Not sure whether you’re going to wake up in the green or red, uncertain of how long you’ll be up or down? You’re not the only one and I’m here to tell you it doesn’t have to be this way. I want to introduce you to something I like to call B-5 cash-outs. The key to how you can win four out of five trades can be found right here in this document: My B-5 cash-out strategy doesn’t include any risky options plays or the ability to perfectly time each and every trade. It’s a very straightforward and simple strategy that I have finely tuned and am ready to share with you. The way I discover these winning companies is so consistent that I can’t wait for you to see what I’m talking about… I’ve laid out all of the details in a dossier that you can view right now for no charge. [Click here to see how you can turn four out of five trades into winners using B-5 cash-outs...]( Browse Our Archives [New Bitcoin ETF Launches]( [Coal 2022 Outlook: It’s Back From the Dead!]( [Watch: Solar Fields Forever — Get in on the Ground Floor]( [Investing in Energy Projects That Pay Monthly Royalties]( [Buy Oil Now, Thank Me Later]( --------------------------------------------------------------- This email was sent to {EMAIL}. It is not our intention to send email to anyone who doesn't want it. If you're not sure why you've received this e-letter, or no longer wish to receive it, you may [unsubscribe here](, and view our privacy policy and information on how to manage your subscription. To ensure that you receive future issues of Energy and Capital, please add newsletter@energyandcapital.com to your address book or whitelist within your spam settings. For customer service questions or issues, please contact us for assistance. Energy and Capital, Copyright © 2021, Angel Publishing LLC. All rights reserved. 3 E Read Street, Baltimore, MD 21202. Your privacy is important to us – we will never rent or sell your e-mail or personal information. Please read our [Privacy Policy](. Neither the publisher nor the editors are registered investment advisors. Subscribers should not view this publication as offering personalized legal or investment advice. Read our [Details and Disclosures.](